ALDX Catches Eyes, VLRX Eyeing China, OASM Up More Than 400% YTD

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Aldeyra Therapeutics Inc. (ALDX)

Gained 34.85% to close Wednesday's (Sep.26) trading at $13.35.

News: The Company announced positive results from its phase IIb clinical trial of topical ocular Reproxalap in patients with dry eye disease.

Based on the successful study results, the Company is planning to initiate a phase III program in dry eye disease in 2019.

In after-hours, the Company announced a proposed public offering of common stock.

2. Valeritas Holdings Inc. (VLRX)

Gained 32% to close Wednesday's trading at $1.32.

News: The Company announced that it has begun medical device registration process in China for Its V-Go wearable insulin delivery device.

V-Go won 510(k) clearance from the FDA in 2010 and CE Mark approval in the European Union in 2011.

3. Cellectar Biosciences Inc. (CLRB)

Gained 24.54% to close Wednesday's trading at $3.35.

News: The FDA has granted Orphan Drug Designation to CLR 131, the Company's lead Phospholipid Drug Conjugate product candidate, for the treatment of pediatric osteosarcoma, a rare pediatric cancer.

Cellectar plans to initiate a phase I clinical study evaluating CLR 131 for the treatment of pediatric patients with osteosarcoma, Ewing's sarcoma, rhabdomyosarcoma, neuroblastoma, high-grade glioma and lymphomas.

4. Electromed Inc. (ELMD)

Gained 20.91% to close Wednesday's trading at $6.65.

News: The Company delivered strong top and bottom-line growth for fiscal fourth quarter ended June 30, 2018.

Net income for the recent fourth quarter expanded 18.2% to $1.1 million or $0.13 per share on net revenue of $8.2 million. This compared with net income of $946,000, or $0.11 per share and net revenue of $7.3 million for the three months ended June 30, 2017.

At June 30, 2018, the Company had cash of $7.5 million, long-term debt including current maturities of $1.1 million, working capital of $17.5 million, and shareholders' equity of $21.9 million.

5. Oasmia Pharmaceutical AB (OASM)

Gained 15.05% to close Wednesday's trading at $5.35.

News: No news

Recent event:

On September 20, the Company's investigational drug Apealea received positive CHMP opinion in the European Union for treatment of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer in combination with carboplatin in first relapse. The European Commission takes usually its decision, a legally binding authorisation, after 67 days following the CHMP opinion.

Near-term Catalyst:

-- Submission of Apealea NDA to the FDA in late 2018 or early 2019.

6. XOMA Corporation (XOMA)

Gained 14.23% to close Wednesday's trading at $18.95.

News: No news

Recent event:

On September 21, the Company acquired from Agenus (AGEN) a partial interest position in the rights to potential milestone and royalty payments associated with seven immuno-oncology antibodies currently being developed by Merck and Incyte under their collaborations with Agenus. The clinical assets are in pre-clinical and phase I/II studies.